Salarius Pharmaceuticals, Inc. has adjourned its 2025 Annual Meeting of Stockholders to solicit more votes for proposals outlined in its proxy statement. The meeting did not meet the required quorum and will reconvene on December 31, 2025. Stockholders as of October 24, 2025, are encouraged to vote online or by phone. The company’s subsidiary, Decoy Therapeutics Inc., is focused on developing peptide conjugate drug candidates for respiratory viruses and GI cancers. Salarius Pharmaceuticals is a clinical-stage biopharmaceutical company with two drug candidates for cancer patients. For more information, visit their website.

Read more at GlobeNewswire: Salarius Pharmaceuticals Announces Adjournment of Annual